RxDoctor Payments Data

Brent Skiver, DO

Hematology & Oncology · Asheville, NCNPI 1669764064

Payments from drug & device makers

$15,250in general payments, 2019–2025

Across 129 payments — averaging $118.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Ipsen Biopharmaceuticals, Inc$3K
  • Beigene USA, Inc.$2K
  • CTI Biopharma Corp.$1K
  • Caris MPI, Inc.$1K
  • Johnson & Johnson$468
  • plus $2K from 36 others

What the payments were for

  • Consulting fees$7,60250%
  • Speaking & faculty fees$4,88832%
  • Food & beverage$2,71118%
  • Education$510%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,250 in reported general payments places this provider in the 55th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$3,572,974
Medicare patients
866
Services billed
129,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide151$2,482,095
ImbruvicaIbrutinib60$963,644
Lenalidomide53$774,788
CabometyxCabozantinib S-Malate27$676,157
CalquenceAcalabrutinib Maleate49$607,136
BesremiRopeginterferon Alfa-2b-Njft35$575,357
BrukinsaZanubrutinib46$522,945
PromactaEltrombopag Olamine25$389,322
TasignaNilotinib Hcl19$385,418
DopteletAvatrombopag Maleate15$346,873
VenclextaVenetoclax32$259,665
IbrancePalbociclib13$203,616
XtandiEnzalutamide13$185,109
JakafiRuxolitinib Phosphate11$179,862
Abiraterone Acetate21$104,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$40$2,482,095151 claims
NovartisPromacta, Tasigna$181$774,74044 claims
Exelixis Inc.Cabometyx$30$676,15727 claims
AstraZenecaCalquence$70$607,13649 claims
Beigene USA, Inc.Brukinsa$2,409$522,94546 claims
PfizerIbrance, Eliquis, Octagam$181$307,097134 claims
AbbVieVenclexta$4,462$259,66532 claims
Astellas Pharma US IncXtandi$16$185,10913 claims
Incyte CorporationJakafi$44$179,86211 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$23$104,28921 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$32$32,79712 claims
Johnson & JohnsonXarelto$468$11,95517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →